Please submit suggestions to:

December 2018

A Revolution in Cancer Care

AACI's New Initiative Will Establish Best Practices in CAR T Therapy

By Joseph McGuirk, DO

Advances in chimeric antigen receptor T-cell (CAR T) technology are revolutionizing cancer treatment. By early 2018, nearly half of AACI cancer centers were approved to provide CAR T therapies. To establish best practices, AACI spearheaded a CAR T working group that became an initiative this fall. As steering committee chair, I am pleased to take the lead as we usher in the next phase of the initiative.

CAR T is a form of cellular immunotherapy – a rapidly evolving approach that harnesses a patient’s immune system to fight cancer. Immunotherapy is now considered the “fifth pillar” of cancer care, alongside surgery, chemotherapy, radiation, and targeted therapy.